Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|July 20, 2012
Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The NetherlandsMargreet G Franken, Chantal W M van Gils, Jennifer G Gaultney, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch ExperiencesSaskia de Groot, Naomi van der Linden, Margreet G Franken, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 16, 2019
Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanomaBrenda Leeneman, Margreet G Franken, Veerle M H Coupé, et al.
Melanoma Research|April 19, 2021
Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the NetherlandsBrenda Leeneman, Hedwig M Blommestein, Veerle M H Coupé, et al.
Cancers|May 13, 2020
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic TherapyStephanie A Blankenstein, Maureen J B Aarts, Franchette W P J van den Berkmortel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2025
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic modelHedwig M Blommestein, Saskia de Groot, Brenda Leeneman, et al.
ESMO Open|December 2, 2021
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugsM G Franken, B Leeneman, M J B Aarts, et al.
BMC Cancer|March 26, 2021
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trialE E A P Mulder, K de Joode, S Litière, et al.
Cancers|April 25, 2020
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted DrugsBrenda Leeneman, Carin A Uyl-de Groot, Maureen J B Aarts, et al.
Melanoma Research|May 12, 2018
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomesMaartje G Schouwenburg, Anouk Jochems, Brenda Leeneman, et al.
Pageof 6